Alkermes advances ALKS 4230 into monotherapy expansion phase of ARTISTRY-1
Alkermes announced initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate efficacy, safety and tolerability of ALKS 4230 in treating patients with renal cell carcinoma or melanoma. The maximum tolerated dose of ALKS 4230 has not yet been reached. June 12, 2019